Roche Set to Start Two Phase 3 Trials of Gantenerumab in People with Early to Mild Alzheimer’s

Roche Set to Start Two Phase 3 Trials of Gantenerumab in People with Early to Mild Alzheimer’s
The safety and efficacy of Roche’s gantenerumab, a treatment candidate for Alzheimer’s, will be tested in two global Phase 3 clinical trials in patients with early to mild forms of the disease. The studies follow a long research process that defined the therapy’s optimal dose. The GRADUATE1 (NCT03444870) and GRADUATE2 (NCT03443973) trials will both run for two years (104

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.


  1. maria damato says:

    my name is maria damato i live on long island in ny. i have been diagnosed with mild alzheimer’s disease i would like to join your study

    • Niklas Reich says:

      Dear Maria,

      As it is stated in the text above, Roche will run two clinical trials with gantenerumab: GRADUATE1 (NCT03444870) and GRADUATE2 (NCT03443973). These trials will probably start recruiting patients by the end of July 2018.

      If you want to participate, you should contact Roche via email: [email protected].
      When contacting them, you should state a Reference Study ID Number, depending on which trial you want to participate in –> for GRADUATE1, state “WN29922” as reference study ID Number and for GRADUATE2, state “WN39658”.
      I am not affiliated with Roche in any way, thus I cannot tell you if there is a major difference between GRADUATE1 and GRADUATE2. You might just ask Roche directly via the email address I have given you earlier.

      I hope this helps!

  2. Leslie Sanqui says:

    My husband had been diagnosed with Alzheimer’s, we live in Southern California, and I would like for him to participate. At the moment he is taking Memantine and Donepezil, 5 mg each every day. Please let me know if he can participate, and if this is an open trial. Thank you

Leave a Comment

Your email address will not be published. Required fields are marked *